紫杉醇脂质体联合卡培他滨治疗晚期乳腺癌的临床观察

The clinical observation of paclitaxel liposome combined capecitabine for the treatment of advanced breast cancer

目的观察紫杉醇脂质体联合卡培他滨治疗晚期乳腺癌的疗效及不良反应。方法选取2010年4月至2012年4月收治的36例晚期乳腺癌患者,采用紫杉醇脂质体联合卡培他滨化疗。紫杉醇脂质体135mg/m2加入500ml 5%葡萄糖注射液中静脉滴注3h,第1天;口服卡培他滨1000mg/m2,每天两次,第1～14天为1个周期,每21天重复。每2个周期评价疗效和不良反应。结果 36例患者均可评价疗效和不良反应,有效19例(52.8%),其中完全缓解4例(11.1%),部分缓解15例(41.7%)。主要的不良反应为骨髓抑制、恶心呕吐和手足综合征,发生率分别为63.8%、52.8%和50.0%,以Ⅰ度为主,患者均可耐受。结论紫杉醇脂质体+卡培他滨治疗晚期乳腺癌疗效确切,不良反应小,患者耐受性好。

Objective To observe the curative effect and adverse reactions of paclitaxel liposome combined capecitabine for the treatment of advanced breast cancer.Methods From April 2010 to April 2012,36 patients with advanced breast cancer were collected,treated with paclitaxel liposome combined capecitabine chemotherapy.135 mg/m2 paclitaxel liposome was added to 5%GS 500ml and intravenous dripped for 3 hours in the first day.1000 mg/m2 capecitabine were given twice daily from d1-14.After two cycles curative effect and adverse reactions were evaluated.Results The curative effect and adverse reactions of 36 patients can be evaluated.19 cases（52.8%） was RR,including 4（11.1%） CR cases,15（41.7%）PR cases.The main adverse effects were bone marrow suppression,nausea vomiting and extremities syndrome,the incidence rate were 63.8%,52.8% and 50.0% respectively.Most of the adverse reactions are 1 degree.All patients could tolerate.Conclusions Paclitaxel liposome combined capecitabine for the treatment of advanced breast cancer,the curative effect was definitive,adverse reaction was slight and tolerated well.